Related Experiment Video
Updated: Jan 17, 2026

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
From Theory to Practice: A Comprehensive Review of Pseudomyxoma Peritonei Research and Its Implications for Future
Han Gao1, Hongli Wang2, Xiufeng Li1
1Department of Clinical Laboratory, Aerospace Center Hospital, Beijing, China.
Abstract:
Pseudomyxoma peritonei (PMP) is a rare disease characterized by symptoms such as mucinous ascites and omental cake, typically arising from a perforated epithelial tumor of the appendix. Because of its rarity, non-specific histologic characteristics, and slow progression, its pathogenesis and optimal treatment remain subjects of debate. PMP is still a challenging and enigmatic condition. Increasing global attention is being directed toward understanding its pathogenesis and establishing standard treatment approaches. PMP and mucin are inextricably linked. This article highlighted the important role of mucin in the disease's pathogenesis. It also discussed several potential therapeutic strategies for eliminating mucin in PMP. Tumor development and metastasis involve a series of steps that include the interaction between the tumor and the host-derived stromal environment, which promotes angiogenesis and activation of inflammatory cells. Inflammatory cytokines and chemokines play a crucial role in the progression and development of PMP. The microbiome and specific microorganisms may directly influence tumor development, progression, and responses to certain therapies in PMP. Thus, the article summarized the interactions among bacteria, the immune system, and mucin in PMP, focusing on the mechanisms that related to abnormal mucin and tumor growth. This review critically examined the existing literature on the clinical features, pathologic processes, and treatment options in PMP, aiming to guide future research toward identifying novel therapeutic targets and gut-related disease biomarkers.
Insights
Pseudomyxoma peritonei (PMP) is a rare mucinous tumor. This review explores mucin's role in PMP pathogenesis and discusses therapeutic strategies targeting mucin, inflammation, and the microbiome.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Pseudomyxoma peritonei (PMP) is a rare appendiceal tumor characterized by mucinous ascites.
- Its pathogenesis, histology, and optimal treatment remain debated due to rarity and slow progression.
Purpose of the Study:
- To review the role of mucin in PMP pathogenesis.
- To discuss potential therapeutic strategies for PMP.
- To summarize interactions among bacteria, immune system, and mucin in PMP.
Main Methods:
- Literature review of clinical features, pathology, and treatment options for PMP.
- Focus on mucin's role, inflammation, and microbiome interactions.
Main Results:
- Mucin plays a critical role in PMP pathogenesis.
- Inflammatory cytokines, chemokines, and the microbiome influence PMP progression.
- Abnormal mucin and tumor growth mechanisms are interconnected.
Conclusions:
- Understanding mucin, immune, and microbial interactions is key to PMP management.
- Further research is needed for novel therapeutic targets and biomarkers.
- PMP remains an enigmatic condition requiring standardized treatment approaches.
More Related Videos
07:20Intraoperative Detection of Subtle Endometriosis: A Novel Paradigm for Detection and Treatment of Pelvic Pain Associated with the Loss of Peritoneal Integrity
Published on: December 21, 2012
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019